

APPENDIX 2 (as supplied by the authors): Findings by therapeutic category

Table B1: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, hypertension treatments										
	Mixed financing	Universal public financing					Universal social insurance financing			
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic expenditure	\$37.9	\$20.4	\$7.2	\$14.7	\$11.6	\$16.2	\$31.0	\$27.5	\$11.9	\$44.9
Comparator expenditure	\$23.6	\$25.6	\$25.5	\$25.4	\$25.6	\$27.5	\$23.6	\$24.4	\$25.9	\$24.7
Total difference in expenditure per capita	61%	-20%	-72%	-42%	-55%	-41%	31%	13%	-54%	82%
Domestic days per capita	103	86	104	91	124	113	106	158	112	91
Comparator days per capita	121	122	119	120	119	121	123	106	120	120
Difference in volume of therapy	-15%	-30%	-13%	-24%	4%	-7%	-13%	50%	-6%	-24%
Difference in cost per day of therapy	75%	9%	-59%	-18%	-59%	-34%	44%	-37%	-48%	106%
Difference in expenditure per capita resulting from differences in drivers of cost per day of therapy										
Broad mix of therapies	-1%	8%	-14%	4%	-17%	-20%	12%	5%	-10%	13%
Narrow mix of therapies	-2%	4%	-8%	-11%	-27%	-18%	23%	-21%	-1%	26%
Choice Effects - subtotal	-3%	12%	-22%	-7%	-43%	-38%	34%	-16%	-11%	40%
Generic use	1%	10%	-3%	8%	3%	-5%	4%	-9%	-12%	14%
Prices	78%	-13%	-34%	-19%	-18%	8%	6%	-12%	-25%	52%
Price Effects - subtotal	79%	-3%	-37%	-11%	-16%	4%	10%	-21%	-37%	66%
Note: Comparator for each country is the population-weighted sum of all nine other countries studied. Percentage figures for the drivers of cost per day of therapy depict how much higher or lower per capita expenditures are because of differences between the specific country's utilization or pricing patterns and those of the other comparator countries.										

Table B2: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, pain medications

	Mixed financing	Universal public financing					Universal social insurance financing			
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic expenditure	\$30.1	\$22.3	\$6.7	\$18.1	\$18.9	\$20.0	\$18.0	\$31.1	\$11.5	\$35.0
Comparator expenditure	\$22.6	\$23.5	\$23.7	\$23.5	\$23.5	\$24.3	\$24.8	\$20.8	\$24.1	\$23.1
Total difference in expenditure per capita	33%	-5%	-72%	-23%	-20%	-18%	-28%	50%	-52%	51%
Domestic days per capita	20	21	13	14	14	15	17	20	10	17
Comparator days per capita	17	17	18	18	18	18	18	17	18	18
Difference in volume of therapy	18%	25%	-24%	-19%	-19%	-17%	-5%	21%	-42%	-3%
Difference in cost per day of therapy	16%	-30%	-48%	-4%	0%	-1%	-23%	29%	-11%	54%
Difference in expenditure per capita resulting from differences in drivers of cost per day of therapy										
Broad mix of therapies	2%	8%	-6%	0%	-23%	-9%	-38%	19%	-6%	1%
Narrow mix of therapies	-2%	2%	-21%	-21%	18%	-5%	17%	-26%	2%	14%
Choice Effects - subtotal	0%	9%	-26%	-21%	-4%	-14%	-21%	-7%	-4%	16%
Generic use	-6%	2%	-7%	20%	4%	5%	4%	-4%	-1%	7%
Prices	22%	-41%	-15%	-3%	0%	8%	-5%	39%	-6%	31%
Price Effects - subtotal	16%	-39%	-21%	17%	4%	13%	-2%	36%	-7%	38%

Note: Comparator for each country is the population-weighted sum of all nine other countries studied. Percentage figures for the drivers of cost per day of therapy depict how much higher or lower per capita expenditures are because of differences between the specific country's utilization or pricing patterns and those of the other comparator countries.

Table B3: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, lipid lowering treatments

	Mixed financing	Universal public financing					Universal social insurance financing			
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic expenditure	\$20.8	\$18.7	\$3.2	\$7.4	\$5.6	\$12.4	\$18.7	\$6.7	\$12.2	\$28.0
Comparator expenditure	\$12.8	\$13.3	\$13.8	\$13.8	\$13.9	\$14.0	\$12.3	\$16.1	\$13.8	\$13.3
Total difference in expenditure per capita	63%	41%	-77%	-47%	-60%	-11%	52%	-58%	-11%	111%
Domestic days per capita	42	36	39	35	31	43	37	30	39	28
Comparator days per capita	36	36	36	36	37	35	36	39	36	37
Difference in volume of therapy	16%	-1%	6%	-4%	-16%	22%	2%	-23%	7%	-24%
Difference in cost per day of therapy	47%	42%	-83%	-42%	-44%	-33%	50%	-35%	-19%	134%
Difference in expenditure per capita resulting from differences in drivers of cost per day of therapy										
Broad mix of therapies	-15%	14%	-6%	-4%	-8%	-16%	15%	5%	-1%	8%
Narrow mix of therapies	46%	37%	-20%	-26%	-26%	-42%	26%	-43%	-13%	17%
Choice Effects - subtotal	31%	50%	-26%	-31%	-35%	-58%	40%	-39%	-14%	25%
Generic use	-44%	12%	-4%	22%	4%	22%	14%	2%	10%	10%
Prices	59%	-20%	-53%	-34%	-14%	2%	-5%	1%	-15%	99%
Price Effects - subtotal	15%	-8%	-57%	-12%	-10%	25%	10%	3%	-5%	110%

Note: Comparator for each country is the population-weighted sum of all nine other countries studied. Percentage figures for the drivers of cost per day of therapy depict how much higher or lower per capita expenditures are because of differences between the specific country's utilization or pricing patterns and those of the other comparator countries.

Table B4: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, non-insulin diabetes treatments

	Mixed financing	Universal public financing					Universal social insurance financing			
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic expenditure	\$21.4	\$7.9	\$0.7	\$8.1	\$6.9	\$13.2	\$14.6	\$13.9	\$4.3	\$16.3
Comparator expenditure	\$12.4	\$13.8	\$13.6	\$13.5	\$13.6	\$13.4	\$13.0	\$13.2	\$13.9	\$13.3
Total difference in expenditure per capita	73%	-43%	-95%	-40%	-49%	-1%	12%	6%	-69%	23%
Domestic days per capita	26	16	15	13	16	20	21	20	20	14
Comparator days per capita	19	20	20	20	20	20	20	20	20	20
Difference in volume of therapy	34%	-19%	-25%	-33%	-18%	1%	4%	-3%	0%	-29%
Difference in cost per day of therapy	39%	-24%	-70%	-7%	-31%	-2%	8%	9%	-69%	52%
Difference in expenditure per capita resulting from differences in drivers of cost per day of therapy										
Broad mix of therapies	-1%	-1%	-7%	-1%	-1%	2%	0%	-1%	-2%	-1%
Narrow mix of therapies	-14%	-13%	-43%	9%	-20%	-22%	9%	23%	-37%	29%
Choice Effects - subtotal	-15%	-14%	-51%	8%	-21%	-20%	9%	22%	-39%	28%
Generic use	-2%	1%	-3%	1%	-1%	2%	0%	9%	-2%	3%
Prices	56%	-12%	-17%	-16%	-9%	17%	-1%	-22%	-28%	20%
Price Effects - subtotal	54%	-10%	-19%	-15%	-10%	18%	-1%	-13%	-30%	24%

Note: Comparator for each country is the population-weighted sum of all nine other countries studied. Percentage figures for the drivers of cost per day of therapy depict how much higher or lower per capita expenditures are because of differences between the specific country's utilization or pricing patterns and those of the other comparator countries.

Table B5: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, gastrointestinal preparations

	Mixed financing	Universal public financing					Universal social insurance financing			
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic expenditure	\$22.7	\$12.6	\$2.4	\$5.7	\$5.0	\$7.3	\$15.0	\$8.6	\$4.2	\$23.0
Comparator expenditure	\$10.0	\$11.4	\$11.6	\$11.6	\$11.7	\$12.5	\$10.5	\$12.5	\$11.9	\$11.2
Total difference in expenditure per capita	127%	11%	-79%	-51%	-57%	-42%	42%	-31%	-65%	106%
Domestic days per capita	33	31	30	23	26	41	37	32	39	30
Comparator days per capita	35	35	35	35	35	33	34	36	34	35
Difference in volume of therapy	-5%	-12%	-14%	-35%	-25%	23%	7%	-12%	13%	-13%
Difference in cost per day of therapy	131%	23%	-66%	-16%	-32%	-64%	35%	-20%	-77%	119%
Difference in expenditure per capita resulting from differences in drivers of cost per day of therapy										
Broad mix of therapies	54%	19%	-13%	-14%	-7%	-19%	45%	-47%	-20%	22%
Narrow mix of therapies	-50%	4%	-14%	13%	-10%	-7%	-21%	39%	-11%	-19%
Choice Effects - subtotal	3%	22%	-28%	-1%	-16%	-26%	23%	-9%	-30%	3%
Generic use	-5%	21%	-4%	14%	1%	-17%	4%	-8%	0%	16%
Prices	133%	-20%	-34%	-29%	-16%	-21%	7%	-3%	-47%	101%
Price Effects - subtotal	128%	1%	-38%	-15%	-16%	-38%	12%	-11%	-47%	117%

Note: Comparator for each country is the population-weighted sum of all nine other countries studied. Percentage figures for the drivers of cost per day of therapy depict how much higher or lower per capita expenditures are because of differences between the specific country's utilization or pricing patterns and those of the other comparator countries.

Table B6: Level and drivers of differences in estimated 2015 expenditure per capita in each country compared to the other nine comparator countries combined, antidepressants

	Mixed financing	Universal public financing					Universal social insurance financing			
	Canada	Australia	New Zealand	Norway	Sweden	UK	France	Germany	Netherlands	Switzerland
Domestic expenditure	\$24.8	\$9.2	\$2.9	\$4.7	\$7.5	\$11.4	\$8.4	\$9.2	\$4.6	\$23.6
Comparator expenditure	\$9.4	\$11.3	\$11.3	\$11.3	\$11.3	\$11.1	\$11.9	\$11.8	\$11.5	\$10.8
Total difference in expenditure per capita	163%	-19%	-74%	-58%	-33%	3%	-30%	-22%	-60%	118%
Domestic days per capita	35	32	27	22	31	36	19	20	17	21
Comparator days per capita	25	25	26	26	26	23	28	28	26	26
Difference in volume of therapy	44%	24%	3%	-16%	21%	52%	-32%	-29%	-36%	-19%
Difference in cost per day of therapy	119%	-43%	-77%	-42%	-54%	-49%	2%	6%	-24%	137%
Difference in expenditure per capita resulting from differences in drivers of cost per day of therapy										
Broad mix of therapies	-1%	-1%	-2%	-2%	-1%	0%	2%	0%	-1%	-1%
Narrow mix of therapies	53%	38%	-39%	-18%	-14%	-55%	6%	4%	-1%	19%
Choice Effects - subtotal	52%	37%	-41%	-20%	-15%	-55%	9%	4%	-2%	19%
Generic use	-4%	-3%	-19%	12%	-10%	5%	4%	-4%	-3%	31%
Prices	71%	-77%	-18%	-33%	-29%	1%	-10%	7%	-19%	87%
Price Effects - subtotal	67%	-80%	-36%	-22%	-39%	6%	-7%	3%	-22%	118%

Note: Comparator for each country is the population-weighted sum of all nine other countries studied. Percentage figures for the drivers of cost per day of therapy depict how much higher or lower per capita expenditures are because of differences between the specific country's utilization or pricing patterns and those of the other comparator countries.